Click here for the full release: RMH PR
Baroness Susan Greenfield will be cutting the ribbon to open HEADWAY, Oxfordshire’s brand new Activity & Rehabilitation Centre. More Information –>
Headway Oxfordshire 5 May 17 Invite
HEADWAY Oxfordshire support people affected by acquired brain injury across Oxfordshire.
Susan Greenfield’s latest interview in The Australian – Click here to read full article
We are pleased to announce that the European Patent Office intends to grant our application for a patent – Neurodegenerative Disorders
Neuro-Bio Ltd Application No. 14736948.2
Click here to read the full Press Release –> Neuro-Bio press release for release 17th March
Friday 19 May 2017 at 10:00 – World Precision Medicine Congress 2017, Business Design Centre, 52 Upper Street, Islington, London N1 0QH – Precision medicine and neurodegenerative disease
Tuesday 6 June/Wednesday 7 June 2017 – OECD Forum Paris, France – Details still to be finalised
Congratulations to Sara Garcia-Rates on her return from maternity leave and to Emily Smith whoa gave birth to Amelia in December
For the full article, please click here.
Neuro-Bio Ltd. has identified a peptide derived from AChE — the enzyme responsible for breaking down acetylcholine — and believes the fragment is the main pathological driver in Alzheimer’s disease, acting upstream of β-amyloid and tau in the brain centers hit earliest in the disease.
Neuro-Bio Ltd are delighted to announce that we have been short listed for the BioNewsRound Award. Our CEO, Susan Greenfield will be presenting a short presentation at the ON Helix Welcome Reception on 27th June. You can find out more information on their website, here.
Published in In Vivo
The US FDA has approved six drugs to treat Alzheimer’s symptoms, all of which work by increasing the amount of neurotransmitters in the brain, helping nerve cells in the brain to communicate. These approved therapies are: Razadyne (galantamine), Exelon (rivastigmine), Aricept, Namenda,Namzaric (memantine + donepezil) and Cognex, which is no longer widely sold in the US. None of these drugs prevent or treat the cause of Alzheimer’s, nor do they slow progression of the disease.